Current Rating and Its Significance
The 'Buy' rating assigned to Asarfi Hospital Ltd indicates a positive outlook on the stock’s potential for investors seeking growth opportunities within the hospital sector. This recommendation suggests that the stock is expected to deliver returns above the market average, supported by a combination of solid financial health, attractive valuation, and favourable technical indicators. Investors should understand that this rating reflects a balanced assessment of the company’s strengths and risks as of today, rather than solely relying on past performance or historical data.
Quality Assessment: Average but Stable
As of 25 December 2025, Asarfi Hospital Ltd holds an average quality grade. This reflects a stable operational foundation with consistent earnings growth and manageable debt levels. The company’s ability to service its debt remains strong, demonstrated by a low Debt to EBITDA ratio of 1.44 times, which indicates prudent financial management and limited leverage risk. While the quality grade does not denote exceptional operational excellence, it confirms that the company maintains a reliable business model within the hospital sector.
Valuation: Attractive Entry Point
The valuation grade for Asarfi Hospital Ltd is classified as attractive, signalling that the stock is reasonably priced relative to its earnings and capital employed. The company’s Return on Capital Employed (ROCE) stands at 8.6%, which, combined with an Enterprise Value to Capital Employed ratio of 3.2, suggests efficient use of capital and a favourable cost structure. Moreover, the PEG ratio of 0.2 highlights that the stock’s price is low compared to its earnings growth potential, making it an appealing option for value-conscious investors.
Register here to know the latest call on Asarfi Hospital Ltd
- - Fundamental Analysis
- - Technical Signals
- - Peer Comparison
Financial Trend: Very Positive Momentum
The financial trend for Asarfi Hospital Ltd is very positive, reflecting robust growth in profitability and sales. As of 25 December 2025, the company has reported a 34.38% increase in net profit, with the latest quarterly results showing a Profit Before Tax Less Other Income (PBT LESS OI) of ₹4.89 crores, which has surged by 122.3% compared to the previous four-quarter average. Net sales for the quarter reached a record ₹44.89 crores, while Profit Before Depreciation, Interest, and Taxes (PBDIT) hit a high of ₹8.87 crores. These figures underscore the company’s strong operational performance and its ability to sustain growth over consecutive quarters.
Technicals: Bullish Outlook
From a technical perspective, Asarfi Hospital Ltd maintains a bullish grade, indicating positive price momentum and favourable chart patterns. The stock has delivered impressive returns, with an 86.00% gain over the past year as of 25 December 2025, significantly outperforming the broader BSE500 index, which returned 6.20% over the same period. Despite a minor 10.47% decline in the last month, the three- and six-month returns remain strong at +46.17% and +42.69% respectively, signalling sustained investor confidence and upward price trends.
Market Capitalisation and Sector Context
Asarfi Hospital Ltd is classified as a microcap within the hospital sector, which often entails higher volatility but also greater growth potential. The company’s market-beating performance and attractive valuation metrics position it well among peers in the healthcare space. Investors looking for exposure to the hospital sector with a focus on growth and value may find this stock aligns with their portfolio objectives.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Investor Takeaway
For investors, the 'Buy' rating on Asarfi Hospital Ltd reflects a stock that combines solid financial health, attractive valuation, and positive technical momentum. The company’s ability to generate strong profit growth and maintain low leverage reduces downside risk, while its valuation metrics suggest room for further appreciation. The bullish technical outlook supports the case for continued price strength, making this stock a compelling option for those seeking exposure to the hospital sector’s growth potential.
It is important to note that while the rating was updated on 14 Nov 2025, all financial data and returns discussed here are current as of 25 December 2025. This ensures investors have the latest information to make informed decisions based on the company’s present-day fundamentals and market performance.
Summary of Key Metrics as of 25 December 2025
- Mojo Score: 77.0 (Buy Grade)
- Debt to EBITDA Ratio: 1.44 times (Low leverage)
- Net Profit Growth: +34.38%
- PBT LESS OI Quarterly Growth: +122.3%
- Net Sales Quarterly: ₹44.89 crores (Highest recorded)
- PBDIT Quarterly: ₹8.87 crores (Highest recorded)
- ROCE: 8.6%
- Enterprise Value to Capital Employed: 3.2
- PEG Ratio: 0.2 (Indicates undervaluation relative to growth)
- 1-Year Stock Return: +86.00%
- BSE500 1-Year Return Benchmark: +6.20%
These metrics collectively underpin the current 'Buy' rating and highlight the stock’s potential as a growth-oriented investment within the hospital sector.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →
